Iodine Supplementation in Mildly Iodine-Deficient Pregnant Women Does Not Improve Maternal Thyroid Function or Child Development: A Secondary Analysis of a Randomized Controlled Trial

Nicole J. E. Verhagen¹, Sueppong Gowachirapant², Pattanee Winichagoon², Maria Andersson³, Alida Melse-Boonstra¹ and Michael B. Zimmermann*¹

¹Division of Human Nutrition, Wageningen University and Research, Wageningen, Netherlands, ²Institute of Nutrition, Mahidol University, Nakhon Pathom, Thailand, ³Division of Gastroenterology and Nutrition, Children’s Research Centre, University Children’s Hospital Zurich, Zurich, Switzerland, ⁴Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland

Background: Iodine deficiency during pregnancy may be associated with lower offspring IQ, but there are few data on the safety and efficacy of maternal iodine supplementation on child development. In a previously reported multi-center randomized trial conducted in Thailand and India, we assessed the effect of iodine supplementation in mildly iodine-deficient pregnant women on offspring development. In this secondary analysis of that trial, we report data only from the Thai pregnant women in the study, who were more iodine deficient at entry.

Methods: Pregnant women in Bangkok, Thailand, were randomized to receive daily 200 μg oral iodine or placebo until delivery. We assessed thyroid size and thyroid function during pregnancy and cognitive and motor development at ages 1, 2, and 5.7 years. The trial was registered at www.clinicaltrials.gov/NCT00791466.

Findings: Women (n = 514) entered the trial between November 2008 and March 2011 at a mean ± SD gestational age of 11 ± 2.8 weeks; their median (IQR) UIC was 112 (75, 170) μg/L. Mean compliance with supplementation was 88%. We assessed 397 mothers in the 3rd trimester, 231 infants at age 2 y, and 157 children at mean age 5.7 y. During pregnancy, there was a slightly greater decrease in free and total thyroxine concentrations in the iodine group (p < 0.05). At age 2 years, the iodine group had borderline lower scores for combined fine and gross motor function (p = 0.05), but there were no other significant differences in development. At 5.7 years, there were no significant group differences in child development.

Conclusion: Daily iodine supplementation in mildly iodine deficient pregnant women was associated with small negative effects on maternal thyroxine concentrations, but
Adequate iodine intake is important throughout the life cycle (1), but is particularly critical during pregnancy, as iodine is an essential component of thyroid hormones that are needed for normal fetal development (2, 3). Pregnancy sharply increases the requirement for iodine, and WHO recommends an iodine intake of 250 µg/d for pregnant women, compared to 150 µg/d for non-pregnant women (4). Thus, pregnant women are particularly vulnerable to iodine deficiency (ID) when dietary iodine supply is low. The WHO suggests a median (m) urinary iodine concentration (UIC) < 150 µg/L in a population of pregnant women indicates ID (4).

In regions of severe iodine deficiency (a mUIC in pregnant women of <50 µg/L) and endemic goiter, iodine supplementation in pregnancy improves maternal thyroid status and child neurodevelopment (2). However, whether mild-to-moderate maternal ID (a mUIC of 50–149 µg/L) increases risk for maternal thyroid disorders or low IQ in the offspring is unclear (2). A recent systematic review (5) that examined the effects of iodine supplementation in pregnant women with mild-to-moderate ID (defined as a baseline mUIC of 50–149 µg/L) concluded there is little evidence to support recommendations for iodine supplementation in pregnancy in areas of mild deficiency (6, 7). Iodine supplementation may not be without risk: abrupt increases in iodine intake can impair thyroid function and the fetal thyroid appears particularly vulnerable to this effect (8). A large cross-sectional study in Chinese pregnant women reported a mUIC > 250 µg/L increased risk for mild maternal hypothyroidism (9) and two cohort studies assessing the effect of iodine supplementation in European pregnant women have reported supplementation had negative effects on infant psychomotor development (10–12).

As highlighted by Dineva et al. (5), the best evidence to date on this issue comes from our previous randomized controlled trial (RCT) in which pregnant women in India and Thailand (n = 832) were randomized to receive daily 200 µg oral iodine or placebo until term (13). Iodine supplementation had no significant effect on child neurodevelopment measured at mean age 5.4 years (13). A limitation of this study was that, although overall the baseline mUIC indicated mild iodine deficiency, the mUIC at the 2 study sites differed: in Thailand, the mUIC was 112 µg/L, while in India, the mUIC was 188 µg/L. Thus, many pregnant women enrolled in India may have been iodine sufficient at baseline. Therefore, in this secondary analysis, we have included data from only the Thai cohort, who were more clearly iodine deficient at baseline.

The study was a randomized, placebo-controlled, double-blind intervention trial; the detailed methods have been described previously (13). The study site was Ramathibodi Hospital of Mahidol University in Bangkok, Thailand. At the time of our intervention, household coverage with adequately iodized salt was ≈60% in Thailand, and school-aged children were iodine sufficient based on their median UIC (13). Ethical review boards at Ramathibodi Hospital and at Wageningen University & Research, the Netherlands, approved the study in two steps: the first approval was for studies to 2 years postpartum and the second follow-on approval to 5–6 years postpartum (13). All participating women gave written informed consent, and the study was registered at ClinicalTrials.gov, NCT00791466.

Inclusion criteria were: (1) singleton pregnancy; (2) age 18–40 years; (3) gestational age ≤14 weeks; (4) not lactating; (5) generally healthy; (6) no use of iodine containing supplements. We excluded women with a TSH >6 mIU/L at screening and referred them for treatment. We randomized women, stratified by site, to receive 200 µg iodine given as potassium iodide tablets (Merck, Darmstadt, Germany) or an identical placebo tablet (Merck, Darmstadt, Germany) taken daily until delivery. We gave out tablets at monthly visits and assessed compliance by tablet counting and assessed side effects using a questionnaire (13). At baseline and during the 2nd (20–24 weeks) and 3rd (30–33 weeks) trimester, we measured maternal weight and height, collected venipuncture blood for measurement of thyroid functions, collected a spot urine sample for measurement of UIC; and measured thyroid volume by using ultrasound.

When children were 1, 2, and between 5 and 6 years, we measured height and weight, obtained a spot urine sample and a fingerprick blood sample which was spotted onto filter paper. At 1 and 2 years postpartum, we administered the Bayley Scales of Infant Development (BSID)-III to obtain scores for cognitive, language and motor development (13). The BSID-III raw scores were adjusted for infant's gestational age at birth. In children at 5–6 years, to assess verbal, performance and full-scale IQ, we administered the Wechsler Preschool and Primary Scale of Intelligence (WPPSI)-III (13). To assess executive functions, we used the Behavior Rating Inventory of Executive Function (BRIEF)-P (13). Details of the developmental tests have been previously described (13).

We determined UIC by using spectrophotometry and thyroid function, thyroglobulin and TPO-Ab were measured using immunoassays, as previously described (13). With the exception of TSH and total thyroxine during pregnancy, we used the manufacturer’s reference ranges. For TSH during pregnancy, we used trimester specific reference ranges: 0.1–2.5 mIU/L for 1st
trimester, 0.2–3.0 mIU/L for 2nd trimester, and 0.3–3.0 mIU/L for 3rd trimester (14). For total thyroxine until week 6, we used the reference range of 58–161 nmol/L; from week 7, we increased the upper reference range by 5% per week until week 15; from week 16 until delivery, we multiplied the non-pregnancy reference range by 1.5 and used the resulting range of 87–241.5 nmol/L as a reference (15).

In children, TSH and total thyroxine concentrations were measured on filter paper by fluoroimmunoassay (TSH, DELFIA NeoTSH, PerkinElmer Life Sciences, Turku, Finland; and T4, Delfia Neonatal T4 kit, PerkinElmer Life Sciences). We applied age-specific reference ranges for TSH and total thyroxine as supplied by the manufacturer: TSH 0.1–3.7 mIU/L and total thyroxine 65–165 nmol/L.

**Data and Statistical Analysis**

As described previously (13), to discriminate a 5-point difference on the full scale IQ score of the WPPSI-III between groups at 5 and 6 years, with a standard deviation of 15, a of 0.05 (two-sided), and 80% power, we estimated we would need 142 children in each group. We used WHO criteria based on the mUIC to classify adequate iodine intake for pregnant women (≥150 μg/L) infants and children (≥100 μg/L) (4). Overt hypothyroidism was defined as a high TSH and a low total thyroxine; subclinical hypothyroidism as a high TSH and a normal total thyroxine; isolated hypothyroxinemia (in the pregnant women) was defined as a normal TSH and a low total thyroxine; overt hyperthyroidism was defined as a low TSH and a high total thyroxine; subclinical hyperthyroidism as a low TSH and a normal total thyroxine. From the thyroid ultrasound measurements, we calculated thyroid volume as previously described (4).

We conducted data analysis with the R statistical programming environment (version 3.6.1) (16) using packages nlme and lme4, as previously described (13). Data were presented as mean (±SD) for normally distributed data, median (IQR) for non-normal data, and percentage (n) for prevalence. We assessed the intervention effect by fitting linear mixed effects models to continuous dependent variables and by fitting logistic regression mixed effect models, as previously described, with two additional fixed effects defined as tertile and tertile by time. Statistical significance was set at $P < 0.05$.

**RESULTS**

We recruited subjects between November 2008 and March 2011, and completed the data collection in July 2016. We assessed 709 participants for eligibility; 195 declined to participate or did not meet the inclusion criteria (Figure 1). 514 pregnant women were enrolled and randomized to the two groups. Participants’ baseline characteristics are shown in Table 1. In the iodine and placebo groups, mean (±SD) gestational age at trial entry was 10.9 (2.8) and 11.0 (2.9) weeks and mUIC (IQR) was 112 (76–163) and 110 (70–172) μg/L, indicating mild iodine deficiency (4). There were no significant differences between the groups in any of the baseline variables, with the exception of a slightly higher free thyroxine in the iodine group ($p = 0.04$) (Table 1). The prevalence of mild thyroid hypofunction, that is, isolated hypothyroxinemia and/or subclinical hypothyroidism, was about 12% in both groups.

Mean compliance with supplementation was 88%. Table 2 shows the maternal variables during pregnancy, by group. We analyzed data from 412 women in the 2nd trimester and 394 women in the 3rd trimester. In the 2nd and 3rd trimesters, mUIC in the iodine group was 224 and 233 μg/L, indicating clear iodine sufficiency in the iodine group (4), while in the placebo group, it was 144 and 155 μg/L, suggesting borderline iodine sufficiency ($p < 0.001$). During pregnancy, maternal free and total thyroxine concentrations were lower in the iodine group as compared to placebo ($p = 0.0003$, and $p = 0.02$, respectively). In a sensitivity analysis based on UIC tertiles during pregnancy restricted to the iodine group, we saw a steeper decline in free and total thyroxine concentrations in women over increasing tertiles of UIC, but these trends were not statistically significant. As expected, maternal thyroglobulin concentrations were lower in the iodine group ($p = 0.0006$). There were no significant group differences in any thyroid disorders (Table 2). The analysis were conducted with and without gestational age as fixed factor, but the results did not change for any of the parameters (data not shown).

We analyzed data from 193 infants at 1 year, 231 infants at age 2 y and 157 children at mean age 5.7 y; attrition was balanced between groups and the main reason was a move away from the trial area around delivery (Figure 1). At age 2 years, the TSH concentrations were lower in the iodine group ($p = 0.03$). We did not observe significant group differences in anthropometrics, UIC and total thyroxine in infants at age 1, 2, and 5.7 years (Table 3). At age 1 year, there were no significant group differences on the BSID-III (Table 4). At age 2 years, the iodine group had lower scores for gross motor ($p = 0.07$) and combined fine and gross motor function ($p = 0.05$) with mean differences [95% CI] of $-0.8 [-1.6$ to 0.03] and $-1.1 [-2.2$ to 0.03], respectively (Table 4). This finding was in part driven by the low motor scores of two children; after removing these two cases from the analysis, the differences in the gross motor and combined motor function scores were reduced (mean diff $= -0.6$, $p = 0.14$ and mean diff $= -0.8$, $p = 0.12$, respectively). At 5.7 years, there were no significant group differences on the WPPSI-III or the BRIEF-P (Table 5). However, on all four measured categories of the WPPSI-III, verbal IQ, performance IQ, processing speed
and full scale IQ, the iodine group had lower scores with mean differences between 0.2 and 2.0 points, although these differences were not statistically significant. As discussed below, a limitation of this secondary analysis is that the sample size at 5.7 years ($n = 157$) was below the estimated sample size needed to discriminate a 5-point difference on the WPPSI (13). All adverse events during

**FIGURE 1** Study overview.
gestation and delivery were recorded; there was no significant group difference in frequency of adverse events: 14 women in the iodine group and 16 in the placebo group experienced adverse events.

**DISCUSSION**

This secondary analysis of our previous RCT provides new insights into the effects of iodine supplementation in mildly iodine deficient women. The Thai pregnant women included in this secondary analysis at baseline had a mUIC of 112 µg/L; this degree of mild maternal iodine deficiency is common worldwide: in national studies of pregnant women in Europe, ≈2/3rds reported mild iodine deficiency based on the mUIC (17). The 200 µg dose of iodine given in this study was effective: in the iodine group, mUIC increased to 224–233 µg/L in the 2nd and 3rd trimesters, at the upper end of mUIC reference range for pregnancy of 150–249 µg/L (4). However, the mUIC in the placebo group also increased to a lesser degree (Table 2); this may have been due to a physiological increase in renal iodine clearance (2) and/or to increased awareness of iodine nutrition and consumption of more iodine-rich foods.

Iodine supplementation was associated with a small but significant negative effect on maternal thyroxine concentrations. Although there was no significant effect on TSH concentrations, free and total thyroxine concentrations declined slightly but significantly more in the iodine group over the duration of pregnancy, as reported before with a different statistical approach (18). The small observed differences in maternal thyroxine concentrations may not be of clinical significance, as there were no significant group differences in maternal hypothyroidism or isolated hypothyroxinemia between groups (Table 2). In seven previous RCTs of maternal iodine supplementation looking at maternal thyroid function (19–26), there were no significant differences in maternal TSH between the iodine and control groups. Six found no significant difference in maternal free (19, 21–24) or total thyroxine concentration (25) between the iodine and control groups, while one found a slightly higher total thyroxine concentration (26) in the iodine group. Another recent intervention study comparing daily administration of a multiple micronutrient supplement containing 300 µg or an iron and folic acid supplement in moderately iodine deficient women (mUIC 51–82) found no differences in maternal TSH or total thyroxine concentration (27). Other intervention studies (that were not RCTs) found no difference in free thyroxine concentrations comparing different doses of iodine supplements (28, 29), but one reported a lower free thyroxine concentration in women receiving iodine supplements (30). One study reported that women who started taking 150 µg iodine/day (as part of a multivitamin/mineral tablet) had a significantly lower free

### TABLE 1 | Baseline characteristics of the Thai pregnant women, by group.

| Age<sup>a</sup>, y | 251 | 30.0 (5.2) | 263 | 29.7 (5.1) |
|---|---|---|---|---|
| BMI, kg/m<sup>2</sup> | 250 | 21.5 (19.5–23.6) | 263 | 21.5 (19.6–23.8) |
| Gestational age, wk | 251 | 10.9 (2.8) | 263 | 11.0 (2.9) |
| First pregnancy, n (%) | 251 | 118 (47) | 263 | 106 (40) |
| Using iodized salt at home, n (%) | 251 | 222 (88) | 263 | 231 (88) |
| Urinary iodine concentration<sup>b</sup>, µg/L | 248 | 112 (76–163) | 260 | 110 (70–172) |
| Thyroid volume, mL | 251 | 8.58 (1.88) | 263 | 8.72 (2.08) |
| Thyroid stimulating hormone, mIU/L | 245 | 1.0 (0.6–1.7) | 258 | 1.1 (0.7–1.7) |
| Thyrogblobulin, µg/L | 232 | 9.38 (4.65–16.53) | 239 | 9.57 (6.36–16.85) |
| Free T<sub>3</sub>, ng/L | 237 | 3.13 (2.70–3.58) | 252 | 3.21 (2.78–3.68) |
| Total T<sub>3</sub>, nmol/L | 248 | 1.85 (1.56–2.15) | 262 | 1.85 (1.54–2.19) |
| Free T<sub>4</sub>, ng/L | 240 | 1.08 (0.98–1.20) | 258 | 1.07 (0.95–1.18) |
| Total T<sub>4</sub>, nmol/L | 247 | 118 (101–138) | 259 | 117 (102–135) |
| TPO-Ab, IU/mL | 251 | 17.7 (11.6–24.7) | 263 | 16.2 (11.1–26.1) |
| Raised TPO-Ab >35 IU/mL, n (%) | 251 | 37 (15) | 263 | 40 (15) |
| Isolated hypothyroxaemia, n (%) | 243 | 4 (2) | 256 | 2 (1) |
| Subclinical hypothyroidism, n (%) | 243 | 24 (10) | 256 | 26 (10) |
| Overt hypothyroidism, n (%) | 243 | 0 (0) | 256 | 0 (0) |
| Subclinical hyperthyroidism, n (%) | 243 | 10 (4) | 256 | 11 (4) |
| Overt hyperthyroidism, n (%) | 243 | 3 (1) | 256 | 1 (<1) |

<sup>a</sup>Continuous data were analyzed using linear mixed effect models with non-transformed or transformed dependent variables and frequencies were analyzed using mixed effect logistic regression testing the differences between treatment populations (iodine or placebo).

<sup>b</sup>Mean (±SD) (all such values).
| Table 2: Maternal outcomes in Thai pregnant women, by group. |
|-------------------------------------------------------------|
| **Baseline** | **Second trimester** | **Third trimester** |
| --------------|----------------------|---------------------|
| n | Value (µg/L) | n | Value (µg/L) | n | Value (µg/L) | **P** |
| Urinary iodine concentration | 248 | 112 (76–163) | 167 | 224 (133–345) | 171 | 233 (140–313) | <0.001 |
| Placebo | 260 | 110 (70–172) | 152 | 144 (86–237) | 185 | 155 (108–211) |
| Thyroid volume | 251 | 8.58 (1.88) | 185 | 8.44 (1.92) | 176 | 8.17 (2.05) | 0.59 |
| Placebo | 263 | 8.72 (2.08) | 171 | 8.54 (2.25) | 190 | 8.20 (1.93) |
| Thyroid stimulating hormone | 245 | 1.0 (0.6–1.7) | 173 | 1.2 (0.8–1.8) | 156 | 1.1 (0.7–1.7) | 0.13 |
| Placebo | 258 | 1.1 (0.7–1.7) | 165 | 1.2 (0.8–1.8) | 177 | 1.3 (0.8–1.8) |
| Thyroglobulin | 232 | 9.38 (4.65–16.53) | 167 | 8.60 (4.65–15.45) | 151 | 9.78 (5.50–18.10) | <0.001 |
| Placebo | 239 | 9.57 (6.36–16.85) | 151 | 10.4 (6.65–15.80) | 175 | 11.9 (6.48–22.25) |
| Free tri-iodothyronine | 237 | 3.13 (2.70–3.58) | 162 | 3.35 (2.82–3.99) | 150 | 3.32 (2.96–3.83) | 0.57 |
| Placebo | 252 | 3.21 (2.78–3.68) | 149 | 3.22 (2.89–3.72) | 175 | 3.38 (2.91–3.85) |
| Total tri-iodothyronine, nmol/L | 248 | 1.85 (1.56–2.15) | 180 | 2.38 (2.03–2.77) | 164 | 2.44 (2.13–2.73) | 0.45 |
| Placebo | 262 | 1.85 (1.54–2.19) | 163 | 2.34 (2.00–2.68) | 182 | 2.42 (2.13–2.86) |
| Free thyroxine, ng/dL | 240 | 1.08 (0.98–1.20) | 175 | 0.78 (0.72–0.88) | 161 | 0.77 (0.68–0.84) | <0.001 |
| Placebo | 258 | 1.07 (0.95–1.18) | 162 | 0.81 (0.75–0.88) | 185 | 0.79 (0.71–0.87) |
| Total thyroxine, nmol/L | 247 | 118 (101–138) | 175 | 114 (102–129) | 161 | 113 (100–129) | 0.02 |
| Placebo | 259 | 117 (102–135) | 167 | 116 (102–131) | 182 | 117 (101–131) |
| TPO-Ab, IU/mL | 251 | 17.7 (11.6–24.7) | 183 | 13.7 (8.5–21.6) | 170 | 12.8 (5.5–19.6) | 0.69 |
| Placebo | 263 | 16.2 (11.1–26.1) | 171 | 14.2 (9.0–21.7) | 192 | 11.7 (6.2–18.9) |
| Raised TPO-Ab >35 IU/mL, n (%) | 251 | 37 (15) | 183 | 21 (11) | 170 | 11 (6) | 0.89 |
| Placebo | 263 | 40 (15) | 171 | 15 (9) | 192 | 13 (7) |
| Isolated hypothyroxinaemia, n (%) | 243 | 4 (2) | 170 | 19 (11) | 155 | 13 (8) | 0.98 |
| Placebo | 256 | 2 (1) | 164 | 11 (7) | 176 | 14 (8) |
| Subclinical hypothyroidism, n (%) | 243 | 24 (10) | 170 | 11 (6) | 155 | 5 (4) | 0.57 |
| Placebo | 256 | 26 (10) | 164 | 6 (4) | 176 | 4 (2) |
| Overt hypothyroidism, n (%) | 243 | 0 (0) | 170 | 2 (1) | 155 | 1 (1) | 0.16 |
| Placebo | 256 | 0 (0) | 164 | 0 (0) | 176 | 0 (0) |
| Subclinical hyperthyroidism, n (%) | 243 | 10 (4) | 170 | 4 (2) | 155 | 7 (5) | 0.51 |
| Placebo | 256 | 11 (4) | 164 | 4 (2) | 176 | 4 (2) |
| Overt hyperthyroidism, n (%) | 243 | 3 (1) | 170 | 0 (0) | 155 | 0 (0) | 0.25 |
| Placebo | 256 | 1 (<1) | 164 | 0 (0) | 176 | 0 (0) |
| Sum of thyroid disorders<sup>2</sup>, n (%) | 251 | 41 (16) | 183 | 36 (20) | 170 | 27 (16) | 0.78 |
| Placebo | 263 | 40 (15) | 171 | 21 (12) | 192 | 22 (11) |

<sup>2</sup>Continuous data were analyzed using linear mixed effect models with non-transformed or transformed dependent variables. Frequencies were analyzed using mixed effect logistic regression. The interaction effect of treatment by time was tested while controlling for household average monthly income, maternal education, maternal age and maternal BMI at trial entry.

<sup>b</sup>Median (IQR) (all such values).

<sup>c</sup>Mean (±SD) (all such values).

<sup>d</sup>Sum of the following disorders: isolated hypothyroxinaemia, subclinical hypothyroidism, overt hypothyroidism, subclinical hyperthyroidism, and overt hyperthyroidism.

TPO-Ab, antithyroid peroxidase antibodies.
TABLE 3 | Secondary outcomes in Thai children, at age 1, 2, and 5.7 years, by group.

|                | 1 year |       | P<sup>a</sup> | 2 year |       | P<sup>a</sup> | 5.7 year |       | P<sup>a</sup> |
|----------------|--------|-------|--------------|--------|-------|--------------|----------|-------|--------------|
|                | n | Value |              | n | Value |              | n | Value |              |
| Sex, male, n (%) |        |       |              |        |       |              |        |       |              |
| Iodine         | 92 | 38 (41) | 0.43 | 115 | 50 (43) | 0.56 | 77 | 32 (42) | 0.84 |
| Placebo        | 104 | 49 (47) |       | 118 | 55 (47) |       | 80 | 35 (44) |       |
| Age<sup>b</sup>, years |        |       |              |        |       |              |        |       |              |
| Iodine         | 92 | 1.0 (0.1) | 0.20 | 114 | 2.1 (0.2) | 0.97 | 77 | 5.6 (0.6) | 0.36 |
| Placebo        | 101 | 1.0 (0.1) |       | 117 | 2.1 (0.2) |       | 80 | 5.7 (0.6) |       |
| Bodyweight, kg |        |       |              |        |       |              |        |       |              |
| Iodine         | 92 | 9.3 (1.2) | 0.94 | 113 | 12.3 (2.0) | 0.98 | 77 | 19.7 (4.6) | 0.08 |
| Placebo        | 101 | 9.3 (1.2) |       | 116 | 12.3 (2.0) |       | 80 | 21.0 (6.2) |       |
| Height, cm     |        |       |              |        |       |              |        |       |              |
| Iodine         | 92 | 75.0 (3.5) | 0.21 | 114 | 87.0 (3.6) | 0.74 | 77 | 112.1 (6.0) | 0.32 |
| Placebo        | 101 | 74.6 (3.0) |       | 117 | 86.9 (4.0) |       | 80 | 113.2 (6.4) |       |
| Height-for-age Z score |     |       |              |        |       |              |        |       |              |
| Iodine         | 91 | −0.1 (1.3) | 0.20 | 114 | −0.2 (1.1) | 0.69 | 77 | −0.2 (1.0) | 0.34 |
| Placebo        | 100 | −0.3 (1.1) |       | 117 | −0.3 (1.1) |       | 80 | −0.1 (1.0) |       |
| Stunting, n (%) |        |       |              |        |       |              |        |       |              |
| Iodine         | 91 | 5 (5) | 0.53 | 114 | 6 (5) | 0.77 | 77 | 2 (3) | 0.17 |
| Placebo        | 100 | 4 (4) |       | 117 | 7 (6) |       | 80 | 0 (0) |       |
| Urinary iodine concentration<sup>c</sup>, µg/L |        |       |              |        |       |              |        |       |              |
| Iodine         | 58 | 239 (136–386) | 0.29 | 82 | 231 (149–293) | 0.62 | 77 | 243 (154–350) | 0.70 |
| Placebo        | 64 | 273 (184–438) |       | 86 | 223 (160–325) |       | 78 | 260 (180–311) |       |
| Total thyroxine, nmol/L |        |       |              |        |       |              |        |       |              |
| Iodine         | 75 | 58.5 (41.6–80.9) | 0.39 | 103 | 64.0 (49.3–83.3) | 0.42 | 76 | 80.0 (70.1–91.0) | 0.11 |
| Placebo        | 86 | 60.8 (45.4–88.3) |       | 107 | 62.6 (47.7–79.8) |       | 77 | 83.3 (69.1–99.7) |       |
| Thyroid stimulating hormone, mIU/L |        |       |              |        |       |              |        |       |              |
| Iodine         | 75 | 0.7 (0.6–1.0) | 0.11 | 103 | 0.8 (0.6–1.0) | 0.03 | 76 | 0.9 (0.7–1.1) | 0.12 |
| Placebo        | 86 | 0.8 (0.6–1.0) |       | 107 | 0.9 (0.6–1.1) |       | 77 | 0.9 (0.7–1.2) |       |

<sup>a</sup>Continuous data were analyzed using linear mixed effect models with non-transformed or transformed dependent variables. Frequencies were analyzed using mixed effect logistic regression. The interaction effect of treatment by time was tested while controlling for household average monthly income, maternal education, child's birthweight, child's age and child's sex.

<sup>b</sup>Mean (±SD) (all such values).

<sup>c</sup>Median (IQR) (all such values).

Notably, we found borderline non-significant group differences in child motor outcomes at age 2 years (Table 4). In the Spanish Infancia y Medio Ambiente–Environment and Childhood (INMA) Study cohort, in Valencia (n = 691), maternal supplemental iodine intake of ≥ 150 µg/day, compared with < 100 µg/day, was associated with a significant 5.2-point decrease in psychomotor scores and a 1.8-fold increase in the odds of a psychomotor score < 85 at age 1 year (10). When pooled with the three other sites in INMA (n = 1,519), the overall increase in risk for a psychomotor score < 85 associated with maternal supplemental iodine intake of ≥ 150 µg/day remained significant (OR = 1.7, 95% CI: 1.1, 2.6) (11). When stratified by maternal iodized salt consumption, this increase in risk was greater for women who consumed iodized salt, suggesting that the extra dose of iodine from supplements might result in iodine excess (11). However, these negative effects on child development in the INMA cohort were not confirmed at age 4–5 years (38). Similarly, we found no significant differences in cognitive outcomes at age 5.7 years, but on all four measured
In an observational study from Norway (45), with mean differences between 0.2 and 2.0 points (Table 5), the iodine group had lower scores, BSID-III, Bayley Scales of Infant Development Third Edition.

\[ \text{BSID-III, Cognitive} \]

|              | 1 year | Mean difference (95% CI) | \( P \) | 2 year | Mean difference (95% CI) | \( P^* \) |
|--------------|--------|--------------------------|--------|--------|--------------------------|--------|
| Iodine       | 85     | 42 (40–45)               | 1.1 (0.01 to 2.3) | 0.08   | 62 (59–64)               | −0.2 (−1.4 to 0.9) | 0.52   |
| Placebo      | 92     | 42 (40–43)               |        |        |                          |        |

\[ \text{BSID-III, Language receptive} \]

|              | 1 year | Mean difference (95% CI) | \( P \) | 2 year | Mean difference (95% CI) | \( P^* \) |
|--------------|--------|--------------------------|--------|--------|--------------------------|--------|
| Iodine       | 85     | 12 (11–13)               | 0.4 (−0.04 to 0.8) | 0.18   | 26 (24–29)               | 0.5 (−0.7 to 1.7) | 0.60   |
| Placebo      | 90     | 12 (11–12)               |        |        |                          |        |

\[ \text{BSID-III, Language expressive} \]

|              | 1 year | Mean difference (95% CI) | \( P \) | 2 year | Mean difference (95% CI) | \( P^* \) |
|--------------|--------|--------------------------|--------|--------|--------------------------|--------|
| Iodine       | 85     | 13 (11–14)               | −0.05 (−0.8 to 0.7) | 0.65   | 29 (26–31)               | 0.9 (−0.4 to 2.3) | 0.38   |
| Placebo      | 90     | 13 (12–15)               |        |        |                          |        |

\[ \text{BSID-III, Language combined} \]

|              | 1 year | Mean difference (95% CI) | \( P \) | 2 year | Mean difference (95% CI) | \( P^* \) |
|--------------|--------|--------------------------|--------|--------|--------------------------|--------|
| Iodine       | 85     | 25 (23–28)               | 0.3 (−0.6 to 1.3) | 0.79   | 55 (50–59)               | 1.5 (−0.8 to 3.8) | 0.40   |
| Placebo      | 90     | 25 (23–27)               |        |        |                          |        |

\[ \text{BSID-III, Fine motor} \]

|              | 1 year | Mean difference (95% CI) | \( P \) | 2 year | Mean difference (95% CI) | \( P^* \) |
|--------------|--------|--------------------------|--------|--------|--------------------------|--------|
| Iodine       | 85     | 29 (28–30)               | 0.3 (−0.3 to 0.9) | 0.41   | 37 (36–39)               | −0.3 (−0.9 to 0.4) | 0.37   |
| Placebo      | 90     | 29 (27–30)               |        |        |                          |        |

\[ \text{BSID-III, Gross motor} \]

|              | 1 year | Mean difference (95% CI) | \( P \) | 2 year | Mean difference (95% CI) | \( P^* \) |
|--------------|--------|--------------------------|--------|--------|--------------------------|--------|
| Iodine       | 84     | 41 (38–44)               | −0.2 (−1.5 to 1.0) | 0.39   | 54 (52–55)               | −0.8 (−1.6 to 0.03) | 0.07   |
| Placebo      | 90     | 41 (38–44)               |        |        |                          |        |

\[ \text{BSID-III, Motor combined} \]

|              | 1 year | Mean difference (95% CI) | \( P \) | 2 year | Mean difference (95% CI) | \( P^* \) |
|--------------|--------|--------------------------|--------|--------|--------------------------|--------|
| Iodine       | 84     | 70 (66–73)               | 0.1 (−1.4 to 1.6) | 0.76   | 91 (89–93)               | −1.1 (−2.2 to 0.03) | 0.05   |
| Placebo      | 90     | 70 (67–73)               |        |        |                          |        |

\( n \) Data were analyzed using linear mixed effect models testing treatment effect while controlling for household average monthly income, maternal education, child’s birthweight, child’s age and child’s sex.

\( \text{BSID-III, Bayley Scales of Infant Development Third Edition.} \)

The women began iodine supplementation at mean gestational age of 11 wk. It is possible that beginning supplementation earlier would have resulted in different findings, as the fetal brain rapidly develops in the 1st trimester (2, 3). However, we did not find an effect of gestational age at entry on any of the developmental outcomes in secondary analysis of the iodine group. We used the mUIC from spot samples to classify population iodine status in pregnant women per recommendations from WHO, but UIC is a poor marker of individual status (4). Thus, it is uncertain whether all women included in this study were iodine deficient and exposure misclassification may have biased our results. The dropout rate was high around delivery but attrition was balanced between groups. The final sample size at 5.7 years \((n = 284)\) needed to discriminate a 5-point difference on the WPPSI between groups; thus, the lack of a group effect on cognitive outcomes at age 5.7 years in this secondary outcome is inconclusive.

In conclusion, in this secondary analysis, daily iodine supplementation with 200 \(\mu g\) iodine in mildly iodine deficient pregnant women did not benefit their thyroid function or improve child development. Iodine supplementation resulted in small but significant negative effects on maternal thyroid function, but did not affect child development. Currently, the American and European Thyroid Associations (6, 7) recommend women take a supplement containing 150 \(\mu g\) iodine daily.
TABLE 5 | Cognitive outcomes in Thai children, at mean age 5.7 years, by group.

|                      | n   | 5.7 years | Mean difference (95% CI) | P<sup>a</sup> |
|----------------------|-----|-----------|--------------------------|--------------|
| WPPSI-III, verbal IQ<sup>b</sup> |     |           |                          |              |
| Iodine               | 77  | 90.9 (±9.2) | −0.5 (−3.5 to 2.6)      | 0.78         |
| Placebo              | 79  | 91.3 (±10.2)|                         |              |
| WPPSI-III, performance IQ |    |           |                          |              |
| Iodine               | 77  | 101.7 (±12.9)| −2.0 (−6.2 to 2.3)     | 0.42         |
| Placebo              | 79  | 103.7 (±14.3)|                         |              |
| WPPSI-III, processing speed |      |           |                          |              |
| Iodine               | 77  | 114.3 (±12.4)| −0.2 (−4.2 to 3.8)    | 0.75         |
| Placebo              | 79  | 114.5 (±13.0)|                         |              |
| WPPSI-III, full scale IQ |     |           | −1.0 (−4.4 to 2.3)     | 0.56         |
| Iodine               | 77  | 97.5 (±10.4) |                         |              |
| Placebo              | 79  | 98.5 (±11.1) |                         |              |
| BRIEF-P, global executive |   |           | 0 (−6.0 to 6.0)         | 0.98         |
| Iodine               | 77  | 112.8 (±19.1) |                         |              |
| Placebo              | 79  | 112.7 (±19.2) |                         |              |

<sup>a</sup>Data were analyzed using linear mixed effect models testing treatment effect while controlling for household average monthly income, maternal education, child’s birthweight, child’s age and child’s sex.

<sup>b</sup>Mean (±SD) (all such values).

BRIEF-P. Behavior Rating Inventory of Executive Function Preschool Version; IQ, intelligence quotient; WPPSI-III, Wechsler Preschool and Primary Scale of Intelligence Third Edition.

during pregnancy. In contrast, WHO does not recommend maternal iodine supplements in countries with iodized salt programs (42), concluding that if women are iodine-replete before they enter pregnancy, they can cover their requirements by increasing fractional clearance of plasma iodide and drawing from thyroidal iodine stores. Our findings suggest current expert recommendations for iodine supplementation in this setting need to be evaluated in large randomized controlled trials that assess both safety and efficacy. Also, it would be valuable for future intervention trials to include pregnant women with moderate iodine deficiency (e.g., with a mUIC <100 μg/L).

REFERENCES

1. Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders. *Lancet Diabetes Endocrinol.* (2015) 3:286–95. doi: 10.1016/S2213-8587(14)70225-6
2. Zimmermann MB. The effects of iodine deficiency in pregnancy and infancy. *Paediatr Perinat Epidemiol.* (2012) 26(Suppl. 1):108–17. doi: 10.1111/j.1365-3016.2012.01275.x
3. Zoeller RT, Rovet J. Timing of thyroid hormone action in the developing brain: clinical observations and experimental findings. *J Neuroendocrinol.* (2004) 16:809–18. doi: 10.1111/j.1365-2826.2004.01243.x
4. World Health Organization, United Nations Children’s Fund, International Council for Control of Iodine Deficiency Disorders. *Assessment of Iodine Deficiency Disorders and Monitoring their Elimination: A Guide for Programme Managers.* Geneva: WHO (2007).
5. Dineva M, Fishpool H, Rayman MP, Mendis J, Bath SC. Systematic review and meta-analysis of the effects of iodine supplementation on thyroid function and child neurodevelopment in mildly-to-moderately iodine-deficient pregnant women. *Am J Clin Nutr.* (2020) 11:389–412. doi: 10.1093/ajcn/nqaa071
6. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosieux C, et al. Guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. *Thyroid.* (2017) 27:315–38. doi: 10.1089/thy.2016.0457
7. Lazarus J, Brown RS, Daumerie C, Huibelaewski-Dydejczyk A, Negro R, Vaidya B. European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. *Eur Thyroid J.* (2014) 3:76–94. doi: 10.1159/000362397
8. Lee SY, Pearce EN. Iodine intake in pregnancy—even a little excess is too much. *Nat Rev Endocrinol.* (2015) 11:260–1. doi: 10.1038/nrendo.2015.28
9. Shi X, Han C, Li C, Mao J, Wang W, Xie X, et al. Optimal and safe upper limits of iodine intake for early pregnancy in iodine-sufficient regions: a cross-sectional study of 7190 pregnant women in China. *J Clin Endocrinol Metab.* (2015) 100:1630–8. doi: 10.1210/jc.2014-3704
10. Murcia M, Rebagliato M, Iniguez C, Lopez-Espinoza MJ, Estarlich M, Plaza Chittacharoen, Mr. Navamin Savirasard, Ms. Duangman Palagrai and Nontima Patcharoros. We thank Dr. Valeria Galetti for advice on statistical analysis.

DATA AVAILABILITY STATEMENT

The data analyzed in this study is subject to the following licenses/restrictions: Dataset can be obtained on request. Requests to access these datasets should be directed to MZ, michael.zimmermann@hest.ethz.ch.

ETHICS STATEMENT

Ethical review boards at Ramathibodi Hospital and at Wageningen University & Research, the Netherlands, approved the study. All participating women gave written informed consent.

AUTHOR CONTRIBUTIONS

SG, AM-B, PW, and MZ designed the study. SG, PW, and AM-B did the field work. SG did the laboratory analyses. NV and MA did the statistical analysis. MZ wrote the first draft of the report. All authors edited and approved the final text.

FUNDING

This study was funded by the Swiss National Science Foundation, Bern, Switzerland; Wageningen University and Research, Wageningen, The Netherlands, the ETH Zurich, Switzerland. Merck (Darmstadt, Germany) supplied the iodine supplements and placebos in-kind.

ACKNOWLEDGMENTS

We thank the mothers and children who participated in the study, and the local study teams and nurses. For the child development assessments, we thank Dr. Nichara Ruangdaraganon, Mrs. Benyachalee Techasensiri and Udon Chittacharoen, Mr. Navamin Savirasard, Ms. Luangman Palagrai and Nontima Patcharoros. We thank Dr. Valeria Galetti for advice on statistical analysis.

SG, AM-B, PW, and MZ designed the study. SG, PW, and AM-B did the field work. SG did the laboratory analyses. NV and MA did the statistical analysis. MZ wrote the first draft of the report. All authors edited and approved the final text.
21. Censi S, Watutantrige-Fernando S, Groccia G, Manso J, Pleban M, Faggian A, et al. Maternal thyroid status is associated with offspring language skills in infancy and toddlerhood. *Nutrients* (2018) 10:1270. doi: 10.3390/nu10091270

22. Pedersen KM, Laurberg P, Iversen E, Knudsen PR, Gregersen HE, Rasmussen H, et al. Iodine intake is associated with thyroid function in mild to moderately iodine deficient pregnant women. *Eur J Nutr.* (2019) 58:28–41. Available online at: https://he01.tci-thaijo.org/index.php/JNAT/article/view/126120

23. Nøhr SB, Jørgensen A, Pedersen KM, Laurberg P. Postpartum thyroid dysfunction in pregnant women from Oviedo area. Is iodine supplementation necessary? *Endocrinol Y Nutr.* (2014) 61:404–9. doi: 10.1016/j.endon.2014.07.004

24. Rebagliato M, Murcia M, Espada M, Álvarez-Pedrerol M, Bolúmar F, Vioque J, et al. Iodine intake and maternal thyroid function during pregnancy. *Epidemiology.* (2010) 21:62–9. doi: 10.1097/EDE.0b013e3181c159b2

25. Abel MH, Korevaar TIM, Erlund I, Villanger GD, Caspersen IH, Arohokana M, et al. Iodine intake in pregnancy among adolescent girls in Iceland. *Am J Clin Nutr.* (2017) 105:853–63. doi: 10.1016/S2213-8587(17)30332-7

26. Silva JE, Silva S. Interrelationships among serum thyroxine, triiodothyronine, reverse triiodothyronine, and thyroid-stimulating hormone in iodine-deficient pregnant women and their offspring: effects of iodine supplementation. *J Clin Endocrinol Metab.* (1981) 52:671–7. doi: 10.1210/jcem-52-4-671

27. Eriksen KG, Andersson M, Hunsizer S, Zimmermann MB, Moore SE. Effects of an iodine-containing prenatal multiple micronutrient on maternal and infant iodine status and thyroid function: a randomised trial in The Gambia. *Thyroid.* (2020) 30:1355–65. doi: 10.1089/thy.2019.0789

28. Santiago P, Velasco I, Muela JA, Sánchez B, Martínez J, Rodríguez A, et al. Infant neurocognitive development is independent of the use of iodised salt or iodine supplements given during pregnancy. *Br J Nutr.* (2013) 110:831–9. doi: 10.1017/S0007114512005880

29. Antonangeli L, Maccherini D, Cavaliere R, Di Giulio C, Reinhardt B, Pichler M, et al. Comparison of two different doses of iodide in the prevention of gestational goiter in marginal iodine deficiency: a longitudinal study. *Eur J Endocrinol.* (2002) 147:29–34. doi: 10.1530/eje.0.1470029

30. Velasco I, Carreira M, Santiago P, Muela JA, García-Fuentes E, Sánchez-Muñoz B, et al. Effect of iodine prophylaxis during pregnancy on neurocognitive development of children during the first two years of life. *J Clin Endocrinol Metab.* (2009) 94:5234–41. doi: 10.1210/jc.2008-2652

31. Meleti M, Di Bella B, Giorgianni G, Mancuso A, De Vivo A, Alibrandi A, et al. Maternal thyroid function in different conditions of iodine nutrition in pregnant women exposed to mild-moderate iodine deficiency: an observational study. *Clin Endocrinol.* (2011) 74:762–8. doi: 10.1111/j.1365-2265.2011.04007.x

32. Marco A, Vicente A, Castro E, Eva Perez C, Rodriguez O, Merchant MA, et al. Patterns of iodine intake and urinary iodine concentrations during pregnancy and blood thyroid-stimulating hormone concentrations in the newborn pregnancy. *Thyroid.* (2010) 20:1295–9. doi: 10.1089/thy.2010.0046

33. Menéndez Torre E, Delgado Alvarez E, Rabal Aartal A, Suárez Gutiérrez L, Rodríguez Caballero MG, Ares Blanco J, et al. Iodine nutrition in pregnant women from Oviedo area. Is iodine supplementation necessary? *Endocrinol Y Nutr.* (2014) 61:404–9. doi: 10.1016/j.endon.2014.07.004

34. Katko M, Gazo AA, Hirsu T, Vartan M, Kovač B, et al. Thyroglobulin level at week 16 of pregnancy is superior to urinary iodine concentration in revealing preconceptual and first trimester iodine supply. *Matern Child Nutr.* (2017) 13:e12470. doi: 10.1111/mcn.12470

35. Manousou S, Andersson M, Eggertsson B, Hunsizer S, Hulthén L, Nyström HF. Iodine deficiency in pregnant women in Sweden: a national cross-sectional study. *Eur J Nutr.* (2019) 59:2355–45. doi: 10.1007/s00394-019-02102-5

36. Rebagliato M, Murcia M, Espada M, Álvarez-Pedrerol M, Bolúmar F, Vioque J, et al. Iodine intake and maternal thyroid function during pregnancy. *Epidemiology.* (2010) 21:62–9. doi: 10.1097/EDE.0b013e3181c159b2

37. Murcia M, Espada M, Juvé S. Iodine status, thyroglobulin levels and thyroid function parameters: results from a randomized controlled clinical trial in a mild-to-moderate iodine deficiency area. *Nutrients.* (2019) 11:2639. doi: 10.3390/nu11112639

38. Pedersen KM, Laurberg P, Iversen E, Knudsen PR, Gregersen HE, Rasmussen OS, et al. Amelioration of some pregnancy-associated variations in thyroid function by iodine supplementation. *J Clin Endocrinol Metab.* (1993) 77:1078–83. doi: 10.1210/jcem-77-4-8409456

39. Nehr SB, Jørgensen A, Pedersen KM, Laurberg P. Postpartum thyroid dysfunction in pregnant thyroid peroxidase antibody-positive women living in an area with mild to moderate iodine deficiency: is iodine supplementation safe? *J Clin Endocrinol Metab.* (2000) 85:3191–8. doi: 10.1210/jcem.85.9.6799

40. de Vasconcellos TJ, Collett-Solberg PF. Perinatal goiter with increased iodine uptake and hypothyroidism due to excess maternal iodine ingestion. *Am J Clin Nutr.* (2012) 96:760–2. doi: 10.3945/ajcn.112.05057

41. Theodoropoulos T, Braverman LE, Vagenakis AG. Iodide-induced hypothyroidism: a potential hazard during perinatal life. *Science.* (1979) 205:502–3. doi: 10.1126/science.451615

42. de Vasconcellos TJ, Collett-Solberg PF. Perinatal goiter with increased iodine uptake and hypothyroidism due to excess maternal iodine ingestion. *Horm Res.* (2009) 72:344–7. doi: 10.1159/000249162

43. WHO Secretariat, Andersson M, de Benoist B, Delange F, Zupan J. Prevention and control of iodine deficiency in pregnant and lactating women and in children less than 2 years-old: conclusions and recommendations of the technical consultation. *Public Health Nutr.* (2007) 10:1606–11. doi: 10.1017/S136898007007361004

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.